Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. ASPIRO trial is most often covered alongside Aspen Neuroscience, which appears in 1 of these 1 story. Each carries 1 original source on average. We currently track 1 Biotech story that mention ASPIRO trial, all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. ASPIRO trial is most often covered alongside Aspen Neuroscience, which appears in 1 of these 1 story. Each carries 1 original source on average. We currently track 1 Biotech story that mention ASPIRO trial, all published on July 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ASPIRO trial. Shared-story counts are live from our verified record — not editorial picks.
Aspen Neuroscience completed dosing in Cohorts 3 and 4 of its ASPIRO trial, bringing total treated patients to 15. The use of a commercial-ready, cryopreserved formulation signals manufacturing maturity and positions the autologous iPSC therapy for pivotal trials. This milestone could shake up the Parkinson's cell therapy race.
Source: prnewswire.com
ASPIRO trial is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
